Given the established association between sarcopenia, systemic inflammation, and reduced efficacy of PD-1 inhibitors in NSCLC [38], these findings underscore the need for future interventions specifically designed to preserve or increase muscle mass. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.